Feasibility, safety, and efficacy of the amber peripheral liquid embolic system: results from stage I of the first-in-human OPAL study
14 affiliations
- 1Department of Interventional Radiology, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
- 2Department of Interventional Radiology, Hospital Ramón y Cajal, Madrid, Spain
- 3Department of Interventional Radiology, Hospital General Universitario Dr Balmis, Alicante, Spain
- 4Department of Interventional Radiology, Hospital Universitari Vall d’Hebron, Barcelona, Spain
- 5Department of Interventional Radiology, Hospital Universitario de Navarra, Pamplona, Barcelona, Spain
- 6Department of Interventional Radiology, Hospital Universitari I Politècnic La Fe Hospital, Valencia, Spain
- 7Department of Interventional Radiology, Hospital Clinic de Barcelona, Barcelona, Spain
- 8Department of Interventional Radiology, Hospital Universitari I Politècnic La Fe Hospital, Data Manager, Valencia, Spain
- 9Department of Interventional Radiology, Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain
- 10Department of Interventional Radiology, Hospital Lozano Blesa, Saragossa, Spain
- 11Department of Interventional Radiology, Interventional Nursing, Hospital Universitari I Politècnic La Fe Hospital, Valencia, Spain
- 12Department of Interventional Radiology, Hospital Universitario Reina Sofía, Córdoba, Spain
- 13Department of Interventional Radiology, Hospital Ribera Povisa, Vigo, Spain
- 14iVascular S.L.U., Sant Vicenç Dels Horts, Barcelona, Spain
Abstract
Purpose: To evaluate the early safety and technical feasibility of Amber 20 for peripheral vascular embolization in a prospective, multicenter, first-in-human stage I study.
Materials and methods: This was a prospective, single-arm, multicenter, open-label first-in-human stage I trial conducted across 11 centers in Spain. Fifteen patients requiring peripheral embolization for various indications (including hemorrhage, aneurysm/pseudoaneurysm, endoleak, portal vein embolization, and hypervascular tumors) were enrolled. The primary endpoint was the rate of device-related serious adverse events (SAEs) within 24 h. Secondary endpoints included overall adverse events (AEs) and technical success, defined as complete vascular occlusion or devascularization on final angiography.
Results: Fifteen patients (60% female; median age 56 years) underwent embolization using Amber 20. Technical success was achieved in 100% of cases (15/15). No device-related SAEs or AEs were reported within 24 h. Five patient (33%) experienced a mild adverse event (postembolization syndrome) related to the procedure. All adverse events resolved without sequelae. No device deficiencies were observed.
Conclusion: In this first-in-human, multicenter study, Amber 20 demonstrated a favorable safety profile and high technical success rate for peripheral vascular embolization. These preliminary findings support its potential as an effective liquid embolic agent, warranting further evaluation in larger studies with longer follow-up (stage II).
Graphical Abstract:
Related
- Feasibility and safety of stand-alone stent retriever thrombectomy for acute embolic mesenteric ischemia in a canine model
- Safety and efficacy of cerebral embolic protection devices during TAVI: a meta-analysis and sequence analysis of trials
- Middle Meningeal Artery Embolization Using Non-Adhesive Liquid Embolic Agents for Chronic Resistant Migraine: Interim Feasibility and Safety Analysis of a Prospective Single-Arm Trial
- Feasibility, Safety, and Preliminary Efficacy of Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease: A 12-Month Pilot Randomized Controlled Trial
- 1180 Interim safety and efficacy results of Victoria-01: a phase 1 study to evaluate the safety and preliminary efficacy of SOT201 in patients with advanced/metastatic solid tumors
BibTeX
@article{serrano2026feasibility,
title = {{Feasibility, safety, and efficacy of the amber peripheral liquid embolic system: results from stage I of the first-in-human OPAL study}},
author = {Elena Serrano and José Urbano and Javier Irurzun and Mercedes Pérez and Iñigo Insausti and Raúl García and Arantxa Gelabert and Serena Pisoni and Roberto Correa and Andrés Guirola and Miguel Cibrán and Juanjo Espejo and Mariano Magallanes and Sara Pich and Aina Fernández and Sofia Valle and Álex Gómez and María Molina and Antonio López-Rueda and Jose Joaquín Martínez and Lluis Duocastella and Fernando M. Gómez and research team of the OPAL study},
journal = {CVIR Endovascular},
year = {2026},
month = nov,
doi = {10.1186/s42155-026-00797-2},
url = {https://doi.org/10.1186/s42155-026-00797-2},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Feasibility, safety, and efficacy of the amber peripheral liquid embolic system: results from stage I of the first-in-human OPAL study
AU - Elena Serrano
AU - José Urbano
AU - Javier Irurzun
AU - Mercedes Pérez
AU - Iñigo Insausti
AU - Raúl García
AU - Arantxa Gelabert
AU - Serena Pisoni
AU - Roberto Correa
AU - Andrés Guirola
AU - Miguel Cibrán
AU - Juanjo Espejo
AU - Mariano Magallanes
AU - Sara Pich
AU - Aina Fernández
AU - Sofia Valle
AU - Álex Gómez
AU - María Molina
AU - Antonio López-Rueda
AU - Jose Joaquín Martínez
AU - Lluis Duocastella
AU - Fernando M. Gómez
AU - research team of the OPAL study
PY - 2026
DA - 2026/11/11
JO - CVIR Endovascular
DO - 10.1186/s42155-026-00797-2
UR - https://doi.org/10.1186/s42155-026-00797-2
AB - Purpose: To evaluate the early safety and technical feasibility of Amber 20 for peripheral vascular embolization in a prospective, multicenter, first-in-human stage I study. Materials and methods: This was a prospective, single-arm, multicenter, open-label first-in-human stage I trial conducted across 11 centers in Spain. Fifteen patients requiring peripheral embolization for various indications (including hemorrhage, aneurysm/pseudoaneurysm, endoleak, portal vein embolization, and hypervascular tumors) were enrolled. The primary endpoint was the rate of device-related serious adverse events (SAEs) within 24 h. Secondary endpoints included overall adverse events (AEs) and technical success, defined as complete vascular occlusion or devascularization on final angiography. Results: Fifteen patients (60% female; median age 56 years) underwent embolization using Amber 20. Technical success was achieved in 100% of cases (15/15). No device-related SAEs or AEs were reported within 24 h. Five patient (33%) experienced a mild adverse event (postembolization syndrome) related to the procedure. All adverse events resolved without sequelae. No device deficiencies were observed. Conclusion: In this first-in-human, multicenter study, Amber 20 demonstrated a favorable safety profile and high technical success rate for peripheral vascular embolization. These preliminary findings support its potential as an effective liquid embolic agent, warranting further evaluation in larger studies with longer follow-up (stage II). Graphical Abstract:
SN - 2520-8934
ER -